PDA

View Full Version : Managed Care Pharmacy Administrative Issues

  1. Biosimilars and patent expirations
  2. Orphan Drug Policy
  3. Generic Lipitor
  4. Generic Concerta?
  5. How to manage first time blockbuster generics
  6. Estimating generic availability for triptans and related combinations
  7. Perceptions of Pharmacists in Managed Care
  8. Biosimilars - How to manage?
  9. Formulary Implications of the Federal Mental Health Parity Act
  10. Understanding and Predicting “At-Risk” Generic Drug Launches: Webinar Follow-Up
  11. Credible Consumer Resources on At-Risk Generics
  12. Difference between At-Risk and Authorized Generics
  13. CMS definition of generic?
  14. Land of the Corporate Giants - Let the Games Begin
  15. PBM fees for e-prescribing
  16. pantoprazole
  17. Estimating generic availability for drugs used in osteoporosis
  18. up-to-date with generics
  19. MTM by non-pharmacists
  20. Estimating generic availability for nasal steroids
  21. Generic Provigil and Nuvigil
  22. Anticholinergic inhalers
  23. Generic albuterol HFA inhaler
  24. Authorized generics and bioequivalence standards
  25. Generic Inhaled Steroids
  26. Generic Aricept and Other Cholinesterase Inhibitors
  27. Day Supply for Stelara Claims
  28. Coding Generics
  29. Generic TZDs and DPP-IV inhibitors
  30. Monitoring market share
  31. Forecasting Generic BPH Agents
  32. Generic Yasmin
  33. Medicare Part-D Payment Issues
  34. Generic Cozaar
  35. external continuous insulin infusion pumps
  36. Breast cancer drugs for men
  37. Contracting for biologics
  38. Generic Ambien CR
  39. Coverage of investigational drugs
  40. Refill-too-soon edit for insulin and related supplies
  41. Estimating generic availability for Kadian, Opana ER and Skelaxin
  42. Practical guide to forecasting generic drug launches: Webinar Follow-up
  43. Generic ANDAs in the context of Citizen Petitions
  44. Generic ANDAs without bioequivalence and different delivery mechanisms
  45. Generic Exclusivity and ANDA information
  46. Estimating Generic Availability for Protonix
  47. Estimating generic availability for Nasacort AQ, Allegra-D, Clarinex and Clarinex-D
  48. Oral oncolytics and dispensing settings
  49. Multiple Atypical Antipsychotics
  50. Hep A vaccine under Medicare
  51. Preventive Pharmacy Benefits
  52. Benefit issues in response to the Swine Flu outbreak
  53. Estimating generic availability for Coreg CR, Diovan and Diovan HCT
  54. PA of oral chemotherpy medications
  55. Generic Adderall XR Issues
  56. Estimating generic availability for Lupron Depot, Eligard and Zoladex
  57. Estimating generic availability for Abilify, Zyprexa, Cymbalta and Lyrica
  58. Revisiting tablet-splitting
  59. Estimating generic availability for Actos, Avandia and related combinations
  60. Specialty Tier Allocation for Medicare Formularies
  61. Utilization of biotech / oncology products
  62. drug utilization by diagnoses
  63. Estimating generic availability for Tricor, Antara, Androgel and Testim
  64. Your experience with Pharmacy benefit transition to 2009
  65. Patent expirations for biologics: will there be cost-savings?
  66. VBID Rx Plans - real or hype without substance?
  67. Estimating generic availability for Pulmicort and Rhinocort
  68. Specialty Pharmacy and PA Administration
  69. Medical Error Reporting
  70. EMR Related Dispensing Error
  71. Estimating generic availability for Adderall XR, Concerta, Medadate CD, Ritalin LA and Provigil
  72. Estimating generic availability for Aciphex, Celebrex and Crestor
  73. Estimating generic availability for Flomax, Casodex, Arimidex, and Thalomid
  74. Future of Managed Care
  75. Are you covering non-FDA approved drugs?
  76. Estimating generic availability for Valtrex, Zerit, Zymar, and Semprex D
  77. Estimating generic availability for Trusopt, Cosopt, Xalatan, and Patanol
  78. Estimating generic availability for Fosamax Plus D, Imitrex, and Asacol
  79. Estimating generic availability for Lexapro, Risperdal M, Metadate CD
  80. What’s your PA process for new members who’ve been receiving treatment prior to enrollment?
  81. Publishing policies for public viewing
  82. Estimating generic availability for Razadyne ER, Aricept, Topamax
  83. Tips for estimating when generics might become available
  84. Are extraordinary drug price increases on your radar?
  85. Market availability
  86. Educating consumers about generic drugs
  87. Value of PAs in complex and costly diseases
  88. Value of comparative effectiveness reviews
  89. Sentinel effect of prior authorization
  90. LICS copay level discrepancy
  91. Sanctioned provider claims for Part D
  92. Controlling sample use
  93. CII day supply limits in PA
  94. Strategies to manage “buy and bill”
  95. Tykerb specialty pharmacy distribution
  96. Vaccine administration under Part D
  97. Self-administered drugs given every 3 months
  98. Medical necessity definition
  99. Medispan SS/MS identifiers
  100. ADHD medication dispensing in MA
  101. Mail order and specialty dispensing laws
  102. First time generic approvals
  103. Compound products
  104. FDB generic/brand codes